B of A Securities Maintains Buy on Karuna Therapeutics, Lowers Price Target to $259
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Gerberry maintains a Buy rating on Karuna Therapeutics (NASDAQ:KRTX) but lowers the price target from $304 to $259.
September 08, 2023 | 3:22 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Karuna Therapeutics' price target has been lowered from $304 to $259 by B of A Securities, though the Buy rating is maintained.
The news is directly related to Karuna Therapeutics. The lowering of the price target might indicate a potential decrease in the stock's value, but the maintained Buy rating suggests that the stock is still expected to perform well. This could lead to mixed reactions in the market, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100